A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

Jeffrey V Lazarus, Ida Sperle, Mojca Maticic, Lucas Wiessing, Jeffrey V Lazarus, Ida Sperle, Mojca Maticic, Lucas Wiessing

Abstract

Background: Fifteen million adults in the World Health Organization European Region are estimated to have active hepatitis C infection. Intravenous drug use is a major hepatitis C transmission route in this region, and people who inject drugs (PWID) constitute a high-risk and high-prevalence population. A systematic review was conducted to assess levels of hepatitis C treatment uptake among PWID in Europe.

Methods: Searches in MEDLINE and EMBASE were carried out for articles in any language published between 1 January 2000 and 31 December 2012. Articles were included in the review if they presented original research findings about hepatitis C treatment uptake levels among people who reported injecting drugs currently or formerly, as well as those who reported using drugs currently or formerly (mode of consumption not specified). Treatment uptake data were extracted if uptake was measurable in relation to the number of patients who either: (a) tested HCV antibody-positive; (b) tested positive for HCV-RNA; or (c) tested positive for HCV-RNA and met additional treatment criteria.

Results: Twenty-five articles from 12 countries were included in the review. Among groups of drug-using study participants who were hepatitis C antibody-positive, the median treatment uptake level was 17%, and among those who were hepatitis C RNA-positive, the median was 30%. In the 11 studies reporting specifically on treatment uptake among current and former injecting drug users, hepatitis C RNA-positive study populations had a median treatment uptake level of 32%. Only one study reported on treatment uptake for current drug users.

Conclusions: This systematic review indicates that hepatitis C treatment uptake is relatively low among drug users in several European countries, and also points to considerable knowledge gaps regarding treatment uptake levels in this population. There was large variability in treatment uptake levels, suggesting that there may be major differences between and within countries in relation to treatment availability, drug-using populations in need of treatment, and the existence of integrated health care services targeting drug users. Stronger national hepatitis C treatment policies are needed, along with efforts to increase knowledge and reduce misconceptions among physicians regarding the feasibility and importance of treating drug users who have hepatitis C.

Figures

Figure 1
Figure 1
Flow diagram of study selection

References

    1. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.
    1. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland; 2014.
    1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
    1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
    1. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014;142:270–286.
    1. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181.
    1. EMCDDA. European Drug Report 2013: Trends and development. Lisbon, Portugal, EMCDDA; 2013.
    1. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ. et al.Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80–S89.
    1. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49:561–573.
    1. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ. et al.Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55:49–57.
    1. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19:829–835.
    1. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57(Suppl 2):S56–S61.
    1. Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013;57(Suppl 2):S51–S55.
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP. et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
    1. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ. et al.Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS One. 2014;9:e103345.
    1. Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, Thau K. et al.Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol. 2009;14:227–237.
    1. Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau PJ, Sabot D, Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010.
    1. Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P. Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly. 2011;141:w13193.
    1. Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol. 2008;20:367–372.
    1. Van Veen M. Briefrapport Infectieziektebestrijding in de verslavingszorg in Nederland. 2009.
    1. Wilkinson M, Crawford V, Tippet A, Jolly F, Turton J, Sims E. et al.Community-based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use. Alimentary Pharmacology and Therapeutics. 2009;29
    1. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V. et al.Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol. 2004;28:533–539.
    1. Gazdag G, Horvath G, Szabo O, Ungvari GS. Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacol Hung. 2010;12:459–462.
    1. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR. et al.Managing chronic hepatitis C acquired through intravenous drug use. QJM. 2001;94:153–158.
    1. Kieran J, Dillon A, Farrell G, Jackson A, Norris S, Mulcahy F. et al.High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. Int J STD AIDS. 2011;22:571–576.
    1. Cullen W, Stanley J, Langton D, Kelly Y, Bury G. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative. Eur J Gen Pract. 2007;13:5–12.
    1. Hernandez FM, Rodriguez San Roman JL, Martin Suarez JM, Pena-Lopez MJ. [Acute hepatitis due to hepatitis C virus infection in the adult population] Gastroenterol Hepatol. 2009;32:677–680.
    1. Perez-Alvarez R, Garcia-Samaniego J, Sola R, Perez-Lopez R, Barcena R, Planas R. et al.Acute hepatitis C in Spain: a retrospective study of 131 cases. Rev Esp Enferm Dig. 2012;104:21–28.
    1. Perut V, Labalette C, Sogni P, Ferrand I, Salmon-Ceron D, Vidal-Trecan G. Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition? Drug Alcohol Depend. 2009;104:78–83.
    1. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A. et al.Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther. 2011;16:815–824.
    1. Backmund M, Meyer K, Von ZM, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188–193.
    1. Grando-Lemaire V, Goisset P, Sorge F, Trinchet JC, Castera L, Roulot D. et al.[Hepatitis C virus screening in drug users in an addiction out-patient unit] Gastroenterol Clin Biol. 2002;26:1091–1096.
    1. Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O. et al.Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction. 2007;102:423–431.
    1. McCormick PA, Keavney M, O'Toole S, Moloney J. Methadone and HCV treatment. Ir Med J. 2008;101:316–317.
    1. Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, Dilg C. et al.Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109:248–251.
    1. Crespo J, Garcia F, Castro B, Pons F. Chronic hepatitis (HCV) among intravenous drug users (IDU); reasons for not initiating the antiviral treatment. [Spanish] Adicciones. 2001;13(36)
    1. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A. et al.Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol. 2005;42:323–328.
    1. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther. 2009;29:38–45.
    1. Kristensen O, Sundoy A, Skeie K, Vederhus JK, Oye I, Opsal A. et al.[Short-term treatment of Hepatitis C in heroin-dependent patients] Tidsskr Nor Laegeforen. 2009;129:1639–1642.
    1. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A. et al.Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011;23:23–31.
    1. World Health Organization. Global policy report on the prevention and control of viral hepatitis. 2013.
    1. World Hepatitis Alliance. Global Community Hepatitis Policy Report. 2014.
    1. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol. 1999;30:956–961.
    1. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–264.
    1. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.
    1. Overbeck K, Bruggmann P, Helbling B. Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment? Eur J Gen Pract. 2011;17:103–108.
    1. John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010;53:245–251.
    1. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K. et al.Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138:123–135.
    1. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29:1051–1055.
    1. Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP. et al.Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:1050–1057.
    1. World Health Organization. Programmatic Update. Antiretroviral Treatment as Prevention (TASP) of HIV and TB. Geneva, World Health Organization; 2012.
    1. Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010;110:228–233.
    1. Vickerman P, Martin N, Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2011;113:83–85.
    1. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54:1137–1144.
    1. Robaeys G, Van VH, Mathei C, Van RM, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18:159–166.
    1. Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J. Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol. 2011;23:32–40.
    1. Medrano J, Resino S, Vispo E, Madejon A, Labarga P, Tuma P. et al.Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat. 2011;18:325–330.
    1. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B. et al.Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8:45–49.
    1. Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir